New phase of development targets chronic pain and fibromyalgia
Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based implant designed to treat chronic pain and fibromyalgia.
The expanded agreement will see Sever Pharma Solutions scale up extrusion processes and continue analytical testing for Silo’s investigational SP-26 polymer implant.
SP-26 is a dissolvable subcutaneous implant that delivers controlled doses of ketamine hydrochloride over time. It aims to provide a safer, non-opioid alternative for long-term pain management.
Sever Pharma Solutions previously supported early development of SP-26, validating the delivery system through long-term in-vitro release testing and drug product characterisation.
The new phase will focus on refining time-released, dose-controlled formulations to enhance therapeutic efficacy and safety.
Silo Pharma CEO Eric Weisblum said: “We are pleased to continue our collaboration with Sever Pharma Solutions as we move forward with further pre-clinical testing of our novel non-opioid chronic pain therapeutic.”
Tony Listro, VP, Technology and Site Lead at Sever Pharma Solutions’ Putnam facility said: “This project together with Silo Pharma exemplifies our commitment to leveraging our specialised capabilities in polymer-based drug delivery systems to help bring novel, non-opioid treatment options closer to patients in need.”
If successful in clinical trials, SP-26 may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, potentially accelerating its route to approval.
